The p53 mutation "gradient effect" and its clinical implications

Abstract

The p53 tumor suppressor-signaling pathway is inactivated in most human cancers. Depending on how p53 is targeted during tumorigenesis impacts whether partial or full tumor suppressor activity is lost. The degree of remaining p53 activity, if any, intuitively impacts the tumor phenotype. This review focuses on recent findings from human cancer studies and genetically engineered mouse models to highlight a p53 functional "gradient effect" and its clinical implications. © 2007 Wiley-Liss, Inc.